WooGene B&G Co. Ltd Asset Resilience Ratio
WooGene B&G Co. Ltd asset resilience ratio. WooGene B&G Co. Ltd (018620) has an Asset Resilience Ratio of 3.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 018620 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of WooGene B&G Co. Ltd (2011–2024)
Asset resilience ratio of WooGene B&G Co. Ltd from 2011 to 2024. This chart shows how WooGene B&G Co. Ltd's Asset Resilience Ratio has changed over time. Read 018620 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down WooGene B&G Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of WooGene B&G Co. Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.92 Billion | 3.35% |
| Total Liquid Assets | ₩3.92 Billion | 3.35% |
Asset Resilience Insights
- Limited Liquidity: WooGene B&G Co. Ltd maintains only 3.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
WooGene B&G Co. Ltd Industry Peers by Asset Resilience Ratio
Compare WooGene B&G Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060 |
Pharmaceuticals | 22.68% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
WooGene B&G Co. Ltd Asset Resilience Ratio by Year (2011–2024)
WooGene B&G Co. Ltd asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for WooGene B&G Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.41% | ₩20.78 Billion ≈ $14.08 Million |
₩112.87 Billion ≈ $76.49 Million |
+3.62pp |
| 2023-12-31 | 14.79% | ₩17.98 Billion ≈ $12.18 Million |
₩121.58 Billion ≈ $82.39 Million |
-12.17pp |
| 2022-12-31 | 26.96% | ₩24.67 Billion ≈ $16.72 Million |
₩91.52 Billion ≈ $62.02 Million |
+6.31pp |
| 2021-12-31 | 20.65% | ₩15.80 Billion ≈ $10.71 Million |
₩76.51 Billion ≈ $51.85 Million |
+4.23pp |
| 2020-12-31 | 16.42% | ₩12.74 Billion ≈ $8.63 Million |
₩77.56 Billion ≈ $52.56 Million |
+9.43pp |
| 2019-12-31 | 6.99% | ₩5.95 Billion ≈ $4.03 Million |
₩85.13 Billion ≈ $57.69 Million |
+2.52pp |
| 2018-12-31 | 4.47% | ₩2.69 Billion ≈ $1.82 Million |
₩60.05 Billion ≈ $40.69 Million |
+3.78pp |
| 2017-12-31 | 0.69% | ₩420.69 Million ≈ $285.09K |
₩60.64 Billion ≈ $41.09 Million |
-9.76pp |
| 2016-12-31 | 10.45% | ₩6.08 Billion ≈ $4.12 Million |
₩58.15 Billion ≈ $39.40 Million |
+7.98pp |
| 2015-12-31 | 2.47% | ₩1.04 Billion ≈ $706.40K |
₩42.24 Billion ≈ $28.63 Million |
+2.19pp |
| 2014-12-31 | 0.28% | ₩81.83 Million ≈ $55.46K |
₩29.06 Billion ≈ $19.70 Million |
-3.00pp |
| 2012-12-31 | 3.28% | ₩858.38 Million ≈ $581.71K |
₩26.18 Billion ≈ $17.74 Million |
+2.44pp |
| 2011-12-31 | 0.84% | ₩216.00 Million ≈ $146.38K |
₩25.81 Billion ≈ $17.49 Million |
-- |
About WooGene B&G Co. Ltd
WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. T… Read more